SecBot SecBot
8-K ·Filed Jul 28, 2026

INCY

INCYTE CORP
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0000879169-26-000053
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The core operational beat (ex-CMS benefit) was solid but not spectacular, 17% net sales growth and 7% Jakafi growth are in line with prior trends. The raised sales guidance is positive, but the massive expense guidance increase from the Vega acquisition will compress near-term GAAP earnings. Watch for the Q3 2026 IPRD charge (~$1.27B) which will create a large GAAP earnings miss, and monitor pipeline catalysts (povorcitinib HS approval, Monjuvi DLBCL launch) for the real value drivers. The stock may initially rally on the headline beat and raised guidance, but the one-time nature of the CMS benefit and the expense overhang suggest limited sustained upside.

DirectionMixed
Confidencehigh
Horizonweeks

Niktimvo

▲ Bullish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially launched (FDA approved August 2024)
Next catalyst
None dated

What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$129.93
T+0 close · Jul 28, 2026 · via day close
Latest settled
−12.69%
T+60 · $113.44
Vs SPY
−17.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 28 $129.93entry
  2. T+1 · 4mo ago −2.18%α −0.64% · $127.10
  3. T+5 · 4mo ago −8.85%α −11.12% · $118.43
  4. T+20 · 3mo ago −0.16%α −3.54% · $129.72
  5. T+60 · 27d ago −12.69%α −17.04% · $113.44
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Incyte reported Q2 2026 GAAP diluted EPS of $2.81 (vs consensus $2.15, +30.7% beat) and total revenue of $1.67B (vs consensus $1.49B, +12.1% beat), driven by a $246M one-time non-cash benefit from a CMS settlement on Opzelura. Excluding that benefit, total net sales grew 17% YoY. The company raised full-year total net sales guidance to $5.13B-$5.26B (from $4.77B-$4.94B) and Opzelura guidance to $1.05B-$1.10B, but also raised operating expense guidance sharply to reflect a $1.27B IPRD charge from the Vega Therapeutics acquisition. The core business (Jakafi +7%, Heme/Onc +69%) is solid, but the headline beat is heavily inflated by a one-time item, and the massive expense guidance increase clouds the forward earnings picture. The stock will likely trade on the raised sales guidance and pipeline progress, but the non-recurring nature of the CMS benefit tempers the bullish read-through for sustainable earnings power.

Key Financial Metrics

EPS
$2.81
est $2.15 · +30.7%
Revenue
$1.7B
est $1.5B · +12.1% · +38.0% YoY
Rating
beat
Guidance
$5,130-$5,260 million
raised

Key Facts

  • Q2 2026 GAAP diluted EPS $2.81 vs consensus $2.15 (beat by 30.7%)
  • Q2 2026 total revenue $1.67B vs consensus $1.49B (beat by 12.1%)
  • Total net sales $1.49B, +40% YoY, but includes $246M one-time non-cash CMS settlement benefit; ex-benefit, net sales grew 17% YoY
  • Jakafi/Jakafi XR net sales $817M, +7% YoY; Opzelura net sales $450M, +173% YoY (ex-benefit +24%)
  • Raised FY2026 total net sales guidance to $5.13B-$5.26B from $4.77B-$4.94B
  • Raised FY2026 GAAP R&D and SG&A expense guidance to $4.915B-$4.995B from $3.495B-$3.675B, reflecting ~$1.27B IPRD charge from Vega Therapeutics acquisition
  • Completed acquisition of Vega Therapeutics for $1.25B upfront, adding latarcibart (Phase 3 for von Willebrand disease)
  • Cash, cash equivalents and marketable securities $4.5B as of June 30, 2026

Financial Impact

Q2 revenue beat consensus by ~$180M, but $246M of that is a one-time non-cash benefit. Raised FY sales guidance by ~$360M at midpoint, but FY GAAP operating expense guidance raised by ~$1.37B at midpoint due to Vega IPRD charge.

revenueepsoperating expensesguidance

Risk Factors

  • $1.27B IPRD charge in Q3 2026 from Vega acquisition will create a large GAAP earnings miss
  • Opzelura CMS settlement is a one-time benefit, core Opzelura growth ex-benefit was 24%, not 173%
  • R&D spend continues to rise (+4% YoY) with 10 Phase 3 studies underway, pressuring margins
  • INCB160058 (JAK2V617F) discontinued, removing a pipeline asset

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
52% bullish (33 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000879169-26-000053
Document: incy-20260728.htm0000879169-26-000053
Document: 0000879169-26-000053-index-headers.html0000879169-26-000053
Document: 0000879169-26-000053-index.html0000879169-26-000053
Document: 0000879169-26-000053.txt0000879169-26-000053
8-K Data (Synthetic)0000879169-26-000053

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 28, 2026